Journal of the Korean Academy of Child and Adolescent Psychiatry

Korean Academy of Child and Adolescent Psychiatry (대한소아청소년정신의학회)
권호 표지
DOI QR코드

DOI QR Code

Off-label or Unlicensed Drug Prescriptions in Child and Adolescent Psychiatry

소아청소년정신과에서의 허가 초과 및 비승인 약물 처방

  • Lee, So-Young Irene (Department of Psychiatry, College of Medicine, Soonchunhyang Bucheon Hospital, Soonchunhyang University)
  • 이소영 (순천향대학교 의과대학 정신과학교실)
  • Received : 2011.06.08
  • Accepted : 2011.06.20
  • Published : 2011.06.30
Download PDF
⟨ Previous Next ⟩

Abstract

The purpose of licensing system is to ensure that the medicines are examined for safety, efficacy and quality. Nevertheless, off-label or unlicensed drug usages in pediatric practice is widespread in Korea and worldwide. Psychotropics are one of the most commonly used off-label or unlicensed drugs. The most valid approach to face this dilemma will be to have more evidences from pediatric pharmacological studies. Clinicians, in addition, need to monitor closely their off-label or unlicensed drug prescriptions to minimize the trial and error in practice. Researchers should publish their experiences and provide guidelines. Pharmaceutical companies, regulatory authorities, and consumer organizations should endeavor altogether for the children's right to get safe and efficacious drugs as adults do. Here, the definition as well as the current status of off-label and unlicensed drug prescriptions will be introduced. Critical issues regarding the off label drugs are discussed. In addition, I will describe the present condition as to the off-label and unlicensed drugs in child and adolescent psychiatry and the authorization process of off-label drug prescription in Korea. Lastly, direction we should like to take in this field will be mentioned.

Keywords

References

  1. Sutherland JM. Fatal cardiovascular collapse of infants receiving large amounts of chloramphenicol. AMA J Dis Child 1959;97:761-767.
  2. Lenz W. Epidemiology of congenital malformations. Ann N Y Acad Sci 1965;123:228-236. https://doi.org/10.1111/j.1749-6632.1965.tb12261.x
  3. Grodin MA, Glantz LH, editors. Children as Research Subjects: Science, Ethics & Law. New York: Oxford University Press; 2004.
  4. Beecher HK. Ethics and clinical research. N Engl J Med 1966;274: 1354-1360. https://doi.org/10.1056/NEJM196606162742405
  5. Rothman DJ. Were Tuskegee and Willowbrook "studies in nature"? Hastings Center Report;1982. p.5-7.
  6. World Medical Association. Declaration of Helsinki. [cited on 8 Jul 2010]. Available from: http://www.wma.net/en/30publications/10po-licies/b3/index.html.
  7. National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, Report and Recommendations. Appendix: Belmont Report: ethical principles and guidelines for the protection of human subjects of research. Washington DC: US Government Printing Office;1979. p.23192-23197.
  8. Department of Health and Human Services. 45 CFR Part 46, Subpart D: protections for children involved as subjects in research. Rockville: Food and Drug Administration;1983. p.9814-9820.
  9. Department of Health and Human Services. 21 CFR Part 201, and 601: regulations requiring ma-nufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Rockville: Food and Drug Administration;1998. p.66632-66672.
  10. US Congress. Food and Drug Administration Modernization Act of 1997 (FDAMA). 1997. Public Law 105-115.
  11. US Congress. Best Pharmaceuticals for Children Act (BPCA). 2002. Public Law 107-109.
  12. US Congress. Pediatric Research Equity Act. 2003. Public Law 108-155.
  13. Committee for Proprietary Medicines (CPMP). Clinical investigation of medicinal products in children. 17-03-1997. Report CP-MP/EWP/462/95. Canary Wharf, London: The European Agency for the Evaluation of Medicinal Products. Human Medicines Evaluation Unit;1997.
  14. European Commission. Better medicines for children. Brussels: DG Enterprise. Unit F2-Paediatric Initiative;2002.
  15. Neubert A, Wong ICK, Bonifazi A, Catapano M, Felisi M, Baiardi P, et al. Defining off-label and unlicensed use of medicines for children: Results of a Delphi Survey. Pharm Res 2008;58:316-322. https://doi.org/10.1016/j.phrs.2008.09.007
  16. Turner S, Nunn AJ, Choonara I. Unlicensed drug use in children in the UK. Paed Perinatal Drug Ther 1997;1:52-55.
  17. Conroy S, Choonara I, Impicciatore P, Mohn A, Arnell H, Rane A, et al. Survey of unlicensed and off label drug use in paediatric wards in European countries. European Network for Drug Investigation in Children. BMJ 2000;320:79-82. https://doi.org/10.1136/bmj.320.7227.79
  18. Blumer JL, Off-label uses of drugs in children. Pediatrics 1999;104: 598-602.
  19. American Academy of Pediatrics. Committee on Drugs. Unapproved used of approved drugs: The Physician, the Package insert, and the Food and Drug Administration. Subject Review. Pediatrics 1996;98:143-145.
  20. DeVeaugh-Geiss J, March J, Shapiro M, Andreason PJ, Emslie G, Ford LM, et al. Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. J Am Acad Child Adolesc Psychiatry 2006;45:261-270. https://doi.org/10.1097/01.chi.0000194568.70912.ee
  21. Hill P. Off licence and off label prescribing in children: litigation fears for physicians. Arch Dis Child 2005;90:17-18. https://doi.org/10.1136/adc.2004.058867
  22. Banner W. Off label prescribing in children. BMJ 2002;324:1290-1291. https://doi.org/10.1136/bmj.324.7349.1290
  23. McIntyre J, Conroy S, Avery A, Corns H, Choonara I. Unlicensed and off label prescribing of drugs in general practice. Arch Dis Child 2000;83:498-501. https://doi.org/10.1136/adc.83.6.498
  24. Bazzano AT, Mangione-Smith R, Schonlau M, Suttorp MJ, Brook RH. Off-label prescribing to children in the United States outpatient setting. Acad Pediatr 2009;9:81-88. https://doi.org/10.1016/j.acap.2008.11.010
  25. Shah SS, Hall M, Goodman DM, Feuer P, Sharma V, Fargason C Jr, et al. Off-label drug use in hospitalized children. Arch Pediatr Adolesc Med 2007;161:282-290. https://doi.org/10.1001/archpedi.161.3.282
  26. Chalumeau M, Tréluyer JM, Salanave B, Assathiany R, Cheron G, Crocheton N, et al. Off label and unlicensed drug use among French office based paediatricians. Arch Dis Child 2000;83:502-505. https://doi.org/10.1136/adc.83.6.502
  27. Ekins-Daukes S, Helms PJ, Simpson CR, Taylor MW, McLay JS. Off-label prescribing to children in primary care: Retrospective observational study. Eur J Clin Pharmacol 2004;60:349-353.
  28. Pandolfini C, Impicciatore P, Provasi D, Rocchi F, Campi R, Bonati M; Italian Paediatric Off-label Collaborative Group. Off-label use of drugs in Italy: A prospective, observational and multicentre study. Acta Paediatr 2002;91:339-347. https://doi.org/10.1111/j.1651-2227.2002.tb01726.x
  29. Muhlbauer B, Janhsen K, Pichler J, Schoettler P. Off-label use of prescription drugs in childhood and adolescence: an analysis of prescription patterns in Germany. Dtsch Arztebl Int 2009;106:25-31.
  30. Hsien L, Breddemann A, Frobel AK, Heusch A, Schmidt KG, Laer S. Off-label drug use among hospitalized children: Identifying areas with the highest need for research. Pharm World Sci 2008;30: 497-502. https://doi.org/10.1007/s11096-008-9193-8
  31. Winterfeld U, Le Heuzey MF, Acquaviva E, Mouren MC, Brion F, Bourdon O. Psychotropic medication use in the child and adolescent psychiatry wards of a French hospital. Pharm World Sci 2008; 30:600-604. https://doi.org/10.1007/s11096-008-9221-8
  32. Hugtenburg JG, Heerdink ER, Tso YH. Psychoactive drug prescribing by Dutch child and adolescent psychiatrists. Acta Paediatr 2005; 94:1484-1487. https://doi.org/10.1080/08035250510036840
  33. Zito JM, Derivan AT, Kratochvil CJ, Safer DJ, Fegert JM, Greenhill LL. Off-label psychopharmacologic prescribing for children: History supports close clinical monitoring. Child Adolesc Psychiatry Ment Health 2008;2:24. https://doi.org/10.1186/1753-2000-2-24
  34. Efron D, Hiscock H, Sewell JR, Cranswick NE, Vance AL, Tyl Y, Luk ES. Prescribing of psychotropic medications for children by Australian pediatricians and child psychiatrists. Pediatrics 2003;111: 372-375. https://doi.org/10.1542/peds.111.2.372
  35. Mehler-Wex C, KÖlch M, Kirchheiner J, Antony G, Fegert JM, Gerlach M. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health 2009;3:14. https://doi.org/10.1186/1753-2000-3-14
  36. Kimland E, Bergman U, Lindemalm S, Bottiger Y. Drug related problems and off-label drug treatment in children as seen at a drug information centre. Eur J Pediatr 2007;166:527-532. https://doi.org/10.1007/s00431-006-0385-8
  37. Schirm E, Tobi H, de Jong-van den Berg LT. Risk factors for unlicensed and off-label drug use in children outside the hospital. Pediatrics 2003;111:291-295. https://doi.org/10.1542/peds.111.2.291
  38. Korean Academy of Child and Adolescent Psychiatry. Clinical Prac-tice Committee report: the off-label medications used by in the me-mbers in the Korean Academy of Child and Adolescent Psychiatry. [accessed on 8 Jul 2010]. Available from http://www.kacap.or.kr.
  39. US Food and Drug Administration. Cumulative list of all products that have received orphan designation: total active designations: 2002. [accessed on 8 Jul 2010]. Available from http://www.fda.gov/ downloads/ForIndustry/DevelopingProductsforRareDiseasesConditions/ HowtoapplyforOrphanProductDesignation/ UCM162066.xls.
  40. Yaffe SJ, Aranda JV. Neonatal and pediatric pharmacology: therapeutic principles in practice, 3rd ed. Philadelphia: WB Saunders; 2005.
  41. Carrey N. Developmental neurobiology: Implications for pediatric psychopharmacology. Can J Psychiatry 2001;46:810-818. https://doi.org/10.1177/070674370104600904
  42. Horen B, Montastruc JL, Lapeyre-Mestre M. Adverse drug reactions and off-label drug use in paediatric outpatients. Br J Clin Ph-armacol 2002;54:665-670. https://doi.org/10.1046/j.1365-2125.2002.t01-3-01689.x
  43. Turner S, Nunn AJ, Fielding K, Choonara I. Adverse drug reactions to unlicensed and off-label drugs on paediatric wards: A prospective study. Acta Paediat 1999;88:965-968. https://doi.org/10.1111/j.1651-2227.1999.tb00191.x
  44. US Food and Drug Administration. Pediatric exclusivity labeling changes. [accessed on 20 Sep 2007]. Available from http://www.fda. gov/cder/pediatric/ labelchange.htm.
  45. Glauser TA. Behavioral and psychiatric adverse events associated with antiepileptic drugs commonly used in pediatric patients. J Child Neurol 2004;19:25-38. https://doi.org/10.1177/088307380401900104
  46. Mirakhur RK. Induction characteristics of propofol in children: Comparison with thiopentone. Anaesthesia 1988;43:593-598. https://doi.org/10.1111/j.1365-2044.1988.tb06699.x
  47. Henney J. Withdrawal of troglitazone and cisapride. JAMA. 2000; 283:2228. https://doi.org/10.1001/jama.283.17.2228
  48. Safer DJ, Zito JM, Gardner JE. Pemoline hepatotoxicity and postmarketing surveillance. J Am Acad Child Adolesc Psychiatry 2001; 40:622-629. https://doi.org/10.1097/00004583-200106000-00006
  49. US Food and Drug Administration. Center for Drug Evaluation and Research;2008.
  50. National Assembly of the Republic of Korea. The system of law knowledge. [accessed on 1 Feb 2011]. Available from URL: http://likms.assembly.go.kr/law/jsp/main.jsp.
  51. Korean Food and Drug Administration. Announcement for medications that cannot be used together and medications that are prohibited in children and adolescents. [accessed on 1 Feb 2011]. Avai-lable from http://www.kfda.go.kr/index.kfda?mid=56&seq=12394
  52. Boos J. Off-label use-label off use? Ann Onco 2003;14:1-5. https://doi.org/10.1093/annonc/mdg035

Cited by

  1. Assessing the risk of type 2 diabetes mellitus among children and adolescents with psychiatric disorders treated with atypical antipsychotics: a population-based nested case–control study vol.27, pp.10, 2018, https://doi.org/10.1007/s00787-018-1123-2
  2. Nationwide Epidemiologic Study of Atypical Antipsychotic Use Among Pediatric Population with Mental Illness in Korea vol.28, pp.3, 2018, https://doi.org/10.1089/cap.2017.0111